Cargando…
P1430: GUT MICROBIOTA DIVERSITY AND BUTYRATE PRODUCERS IMPACTS ON NON-HODGKIN LYMPHOMA PATIENTS RESPONSE TO CD19 CAR-T THERAPY
Autores principales: | Garcia-Vicente, R., Rodriguez-Garcia, A., Gomez-Gordo, R., Ortega-Hernandez, A., Ancos, R., Serrano, S., Modrego, J., Leivas, A., Valeri, A., Jimenez-Ubieto, A., Sanchez-Pina, J. M., Paciello, M. L., Gomez-Garre, D., Martinez-Lopez, J., Linares, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430719/ http://dx.doi.org/10.1097/01.HS9.0000848576.67323.0a |
Ejemplares similares
-
P869: PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM
por: Rodríguez-García, A., et al.
Publicado: (2022) -
1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
por: Rausch, Ethan, et al.
Publicado: (2022) -
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
por: Leivas, Alejandra, et al.
Publicado: (2021) -
Identification of a Plasma Microrna Signature as Biomarker of Subaneurysmal Aortic Dilation in Patients with High Cardiovascular Risk
por: Torres-Do Rego, Ana, et al.
Publicado: (2020) -
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
por: Valeri, Antonio, et al.
Publicado: (2022)